MoneyWorks4Me

Agilus Diagnostics Ltd

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Hospital & Healthcare Services | Small Cap | Agilus Diagnostics Share Price

BSE Share Price
Not Listed

Agilus Diagnostics Ltd

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Hospital & Healthcare Services | Small Cap | Agilus Diagnostics Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹0 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
98.6
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
INF%
Profitability Efficiency
Return on Equity (ROE)
8.32%
Return on Capital Employed (ROCE)
12.03%
Return on Assets (ROA)
6.81%
Operating Profit Margin
23.6%
Net Profit Margin
11.71%
Gross Profit Margin
24.4%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
8.5%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
44.73%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
83.2%
Asset Quality
Promoter Holding
%
Pledged shares (%) of Promoter's holding (%)
%
Reserves
-
Equity
₹52 Cr.
Face Value
₹10
All Time Low / High
- / -

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ12%7.4%9.8%9.7%11.8%17.6%8%4.2%3.4%8.1%-

Growth Parameters ⓘ

Sales ⓘ637681705714775966834859858931677
Sales YoY Gr.-6.9%3.6%1.4%8.4%24.8%-13.7%3%-0.1%8.5%-
Adj EPS ⓘ9.77.17.4811.920.111.54.93.411.76.8
YoY Gr.--27%4.1%8%50.2%68.3%-42.9%-57.2%-30.4%243.3%-
BVPS (₹) ⓘ126.9122.6130137.2149169.2174.8176.8178.5186.7179.8
Adj Net
Profit ⓘ
70.155.457.762.393.61589038.526.992.135
Cash Flow from Ops. ⓘ29.4-30.2-2.713513313477.20.588.1130-
Debt/CF from Ops. ⓘ0.1-0.5-0.700007.200-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ4.3%3.8%3.8%8.5%
Adj EPS ⓘ2.2%-0.3%0.8%243.3%
BVPSⓘ4.4%4.6%2.2%4.6%
Share Price - - - -

Key Financial Parameters ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ
7.95.95.85.98.312.66.72.81.96.43.7
Op. Profit
Mgn % ⓘ
17.614.714.215.317.120.211.96.7714.3NAN
Net Profit
Mgn % ⓘ
118.18.28.712.116.310.84.53.19.95.2
Debt to
Equity ⓘ
0000000000-
Working Cap
Days ⓘ
2322873333663332442842973022930
Cash Conv.
Cycle ⓘ
2460104772111141520120

Valuation of Agilus Diagnostics - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Financials

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales936.81987.301,010.161,016.331,035.071,604.911,347.461,372.041,406.741,526.56
Operating Expenses ⓘ + 766.61828.51825.35839.32860.061,1931,108.491,162.121,158.191,166.83
Manufacturing Costs155.56175.17181.42189.73186.22282.98276.97278.20286.75289.57
Material Costs237.97246.64235.27241.06287.62399.14315.98322320.76336.63
Employee Cost 209.26224.04232.66252.54243.50307.26307.88319.12310.72323.74
Other Costs ⓘ 163.83182.66176155.99142.73203.62207.65242.80239.95216.89
Operating Profit ⓘ 170.19158.79184.81177.01175.01411.91238.98209.92248.55359.72
Operating Profit Margin (%) 18.2%16.1%18.3%17.4%16.9%25.7%17.7%15.3%17.7%23.6%
Other Income ⓘ + 9.117.485.9220.2725.6213.4423.6419.6425.6933.76
Exceptional Items ⓘ 00.35-1.866.720306.14000-16.85
Interest ⓘ 7.855.775.7812.7311.7915.7615.4523.1823.9021.09
Depreciation ⓘ 49.6943.4438.9157.6352.0780.2888.97112.47117.05117.87
Profit Before Tax ⓘ 121.77117.41144.17133.64180.35636.35158.2093.80133.29237.95
Tax ⓘ 35.6942.2453.3748.0749.1081.6541.5727.2235.7559.26
Profit After Tax 86.0875.1890.8185.57131.25554.71116.6466.5897.54178.69
PAT Margin (%) 9.2%7.6%9.0%8.4%12.7%34.6%8.7%4.9%6.9%11.7%
Adjusted EPS (₹)12.79.611.610.916.770.714.98.512.422.8
Dividend Payout Ratio (%)0%0%0%0%0%6.70%20%19.90%19.90%20%
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 924.59999.241,092.471,175.041,3081,863.091,942.511,984.672,067.732,226.61
Share Capital ⓘ 80.3878.4278.4378.4378.4378.4378.4378.4378.4378.44
Reserves ⓘ 844.21920.821,014.051,096.611,229.581,784.661,864.081,906.251,989.312,148.17
Debt +2.4119.982.100.120.971.611.902.461.571.51
Long Term Debt0.100.100.110.120.971.611.902.461.571.51
Short Term Debt2.3119.881.990000000
Minority Interest0000000000
Trade Payables8180.0883.4490.11116.41129.31139.47109.28113.92154.31
Others Liabilities ⓘ 176.55231.84295.12422.05460.49719.42294.17376.41352.63328.37
Total Liabilities ⓘ 1,184.551,331.141,473.131,687.321,885.882,713.432,378.042,472.822,535.862,710.80

Fixed Assets

Net Fixed Assets ⓘ +742.14723.58706.76748.89752.861,520.611,674.271,799.921,781.701,770.04
Gross Block857.29856.91878.66949.451,002.791,798.152,016.572,160.232,235.742,315.61
Accumulated Depreciation115.15133.33171.90200.56249.93277.54342.30360.31454.04545.57
CWIP ⓘ 1.790.631.880.171.112.121.330.437.4718.39
Investments ⓘ 26.2528.9333.7540.2455.873.193.202.502.502.79
Inventories28.033125.1530.5637.5956.7360.9741.2141.8643.37
Trade Receivables146.59246.05337.41145.05144.21149.55143.15148.61161.12177.60
Cash Equivalents 19.5517.0242.96111.95359.01362.22323.69267.13355.27196.02
Others Assets ⓘ 220.20283.92325.21610.44535.21619.01171.44213.01185.94502.59
Total Assets ⓘ 1,184.551,331.141,473.131,687.321,885.882,713.432,378.042,472.822,535.862,710.80
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + 89.3110.4948.60197.52175.86294.85191.13116.73256.25332.76
PBT ⓘ 127.73117.41144.17133.64180.35636.35158.2093.80133.29237.95
Adjustment ⓘ 52.9758.5544.1456.805.65-223.7492.89142.92130.4394.89
Changes in Working Capital ⓘ -48.5-122.22-82.2359.2834.99-11.83-4.71-57.572.8147.74
Tax Paid ⓘ -42.88-43.26-57.49-52.20-45.13-105.93-55.25-62.41-10.27-47.82
Cash Flow From Investing Activity ⓘ + -52.15-27.50-3.35-171.4337.18-398.37-107.20-77.77-190.58-201.21
Capex -23.11-35.11-26.49-30.67-34.69-61.77-140.66-54.33-90.71-69.89
Net Investments -12.330.83-1.35021.18-467.5732.49-38.87-114.58195.87
Others ⓘ -16.716.7924.49-140.7650.69130.970.9715.4414.72-327.18
Cash Flow From Financing Activity ⓘ + -38.06-2.91-2.39-26.27-26.39-33.51-74.17-73.67-67.68-74.46
Net Proceeds from Shares ⓘ 1.420.260.030000000.06
Net Proceeds from Borrowing ⓘ -25.490000.850.640.280.57-1.08-0.14
Interest Paid ⓘ -5.85-3.17-2.42-9.60-9.02-11.93-11.85-17-17.16-16.20
Dividend Paid ⓘ 000000-37.25-23.37-13.25-19.45
Others ⓘ -8.1300-16.67-18.23-22.22-25.34-33.86-36.18-38.73
Net Cash Flow ⓘ -0.89-19.9342.86-0.18186.64-137.039.77-34.70-257.09
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)10.877.858.687.5510.5734.996.133.394.818.32
ROCE (%)14.3312.6114.1212.8415.41419.15.947.7312.03
Asset Turnover Ratio0.860.780.720.640.580.70.530.570.560.58
PAT to CFO Conversion(x)1.040.140.542.311.340.531.641.752.631.86
Working Capital Days
Receivable Days49.5072.60105.4086.605133.4039.6038.8040.2040.50
Inventory Days10.8010.9010.20101210.7015.9013.6010.8010.20
Payable Days120.80119.20126.80131.40131112.40155.20141127145.40

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Agilus Diagnostics Ltd FAQs

The current trading price of Agilus Diagnostics on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Agilus Diagnostics stood at ₹0.00 Cr

The latest P/E ratio of Agilus Diagnostics as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Agilus Diagnostics as of 31-Dec-1969 is 0.00.

The 52-week high of Agilus Diagnostics is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Agilus Diagnostics is ₹677 ( Cr.) .

Data is not available for this company.

No data found

No data found

About Agilus Diagnostics Ltd

Super Religare Laboratories Limited was initially incorporated on July 7, 1995 as specialty Ranbaxy Private Limited, 50:50 joint ventures between Specialty Laboratories Asia Limited and Ranbaxy Laboratories Limited, pursuant to a joint venture agreement dated April 17, 1995 (JV Agreement). Later the name of the company was subsequently changed to  SRL Ranbaxy Limited .The reason for such name change was the termination of the joint venture with Specialty Laboratories Asia Limited on January 18, 2002, consequent to which the company had to drop the trade name specialty  from its name, in accordance with the JV Agreement.

On August 20, 2010, the company acquired 100% of the paid up capital of Piramal Diagnostics Services Private Limited (PDSPL). The company was incorporated in order to undertake the business of establishing, maintaining and managing clinical reference laboratories to provide testing, diagnostic and prognostic monitoring services.

Business Profile:

The company is one of the leading diagnostics services companies in India. Following the acquisition of PDSPL in August 2010, we have the largest market share (48%) in the organized sector in India. The company provides diagnostic testing services (routine, specialized and esoteric tests), preventive care testing services and clinical research trial testing services at their laboratories, and during the nine month period ended December 31, 2010 it has performed approximately 33,000 diagnostic tests per day. It has served more than 4.20 million customers during the nine month period ended December 31, 2010 through their network of reference laboratories, Centers of Excellence, network laboratories (comprising pathology and radiology laboratories), collection centers and wellness centers. As of December 31, 2010, its diagnostic laboratory network comprised eight reference laboratories, seven Centers of Excellence, 181 network laboratories (comprising 164 pathology laboratories and 17 radiology laboratories), 15 wellness centers and 888 collection centers. As of December 31, 2010, of its 164 pathology laboratories, 53 are owned by the company, it operate and manage 31 pathology laboratories based in hospitals (14 of which are based in hospitals run by Fortis Healthcare Limited), 55 are joint venture laboratories and 25 are franchisee laboratories. As of December 31, 2010, of its 17 radiology laboratories, 16 are owned by them and we operate and manage one radiology laboratory based in a hospital. Six of its reference laboratories are based in India, its seventh reference laboratory is based in Kathmandu, Nepal and the company has entered into a service agreement for one reference laboratory in the Dubai Healthcare City.

In addition, currently it is having 23 collection centers, as well as representation and liaison offices, outside India in the United Arab Emirates, Oman, Qatar, Kuwait, Bahrain, Sri Lanka, Bangladesh, Nepal, the Maldives, Tanzania and Zambia.

The company’s reports are used for detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions, as well as to monitor and evaluate responses to medication. Through Piramal Diagnostics, it offer a range of pathology services and radiology modalities including computed tomography (CT), diagnostic radiology (X-ray), magnetic resonance imaging (MRI), ultrasound and positron emission tomography (PET). Its collection centers collect specimens within an area or region for shipment to a pre-designated laboratory for testing and its wellness centers offer inter alia preventive care through various health screening packages.

The company also provides clinical research services, which are dedicated to offering centralized laboratory services to support the needs of drug development for various phases of clinical trials conducted by Indian as well as international pharmaceutical, biotechnological and research companies. Its services extend to support multi-centric studies at sites within India as well as in their neighboring Asian countries.

Top 5 Group Companies:

  • Fortis Healthcare Limited
  • Fortis Malar Hospitals Limited
  • Religare Enterprises Limited
  • Dion Global Solutions Limited - one of the largest Group Company (based on turnover- Fiscal 2010)
  • Religare Securities Limited
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now